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Abstract
Purpose of review—To discuss the current knowledge on the role of connexins and pannexins 
in the musculoskeletal system.
Recent findings—Connexins and pannexins are crucial for the development and maintenance of 
both bone and skeletal muscle. In bone, the existence of connexin and more recently pannexin 
channels in osteoblasts, osteoclasts, and osteocytes has been described, and shown to be essential 
for normal skeletal development and bone adaptation. In skeletal muscles, connexins and 
pannexins play important roles during development and regeneration through coordinated 
regulation of metabolic functions via cell-to-cell communication. Further, under pathological 
conditions, altered expression of these proteins can promote muscle atrophy and degeneration by 
stimulating inflammasome activity.
Summary—In the current review, we highlight the important roles of connexins and pannexins in 
the development, maintenance, and regeneration of musculoskeletal tissues, with emphasis on the 
mechanisms by which these molecules mediate chemical (e.g., ATP and PGE2) and physical (e.g. 
mechanical stimulation) stimuli that target the musculoskeletal system and their involvement in the 
pathophysiological changes in both genetic and acquired diseases.
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Introduction
Connexins and pannexins are channel forming proteins that share similar topology, although 
they do not exhibit sequence homology [1]. Both connexins and pannexins comprise 4 
transmembrane domains, two extracellular and one intracellular loop with the amino- and 
carboxi-terminal regions facing the cytoplasm. Connexins form hexamers or connexons in 
the cell membrane that mediate the exchange of small molecules between the cells and the 
extracellular compartment, named hemichannels [2]. Hemichannels present in adjacent cells 
can align to form gap junction channels, allowing the exchange of molecules between 
neighboring cells [3]. Pannexins also form hexamers in the cell membrane, but most 
investigators agree they are not able to form functional gap junction channels [4,5]. The 
existence of connexin channels in osteoblasts, osteoclasts, and osteocytes has long been 
recognized, and most recently, the presence of pannexin channels has been described in 
these bone cells [3]. In muscle, connexins are only expressed in undifferentiated precursors 
and upon injury in regenerating muscles, whereas pannexins have been reported in both 
precursors and mature muscle cells [6]. In this review, we discuss the current knowledge on 
the role of connexins and pannexins in the musculoskeletal system.
CONNEXINS AND PANNEXINS IN BONE
Connexins and pannexins in bone development, maintenance, and regeneration
The development and maintenance of bone tissue depends on the coordinated actions of 
bone forming osteoblasts and bone resorbing osteoclasts. These actions are controlled by 
osteocytes, differentiated osteoblasts embedded in the bone matrix [7]. Cell-to-cell 
communication via gap junctions among these cells was first appreciated in morphological 
studies using electron microscopy [8]. Connexin 43 (Cx43) is the most abundant member of 
the connexin family of proteins in bone, and it is expressed in osteoclasts, osteoblasts, and 
osteocytes [9–11]. Deletion of Cx43 in global Cx43 knockout mice leads to delayed 
mineralization and deficient osteoblast differentiation in the embryos [12–14]. However, 
mice with global Cx43 deletion die at birth, and therefore the skeletal phenotype of adult 
mice cannot be investigated [15]. Deletion of Cx43 in osteochondroprogenitors or in early 
osteoblast progenitors in mice also results in impaired osteoblast differentiation, suggesting 
a defect inherent to osteoblastic cells [16,17]. These mice exhibit reduced bone mass and 
osteoblast numbers [18]. On the other hand, mice with deletion of Cx43 in more mature cells 
of the osteoblastic lineage (such as cells expressing the col1a1 or DMP1 promoter) exhibit 
minimal, if any, bone defects [19–21]. Interestingly, Cx43fl/fl;Col1a1–2.3kb-Cre mice, in 
which Cx43 is deleted from osteoblast progenitors, mature osteoblasts, and osteocytes 
exhibit defective muscle development, with reduced weight, grip strength, and tetanic forces 
[22]. The decrease in muscle mass results in lower whole body weight, a phenotypic 
characteristic that is absent in mice with deletion of Cx43 in mature osteoblasts and 
osteocytes, or in osteocytes only [19,21], suggesting that Cx43 expression in osteoblast 
precursors is required for optimal muscle development.
Osteoblasts and osteocytes also express Cx45 and Cx46, although the function of these 
connexins in bone cells is not known [23–25]. More recently, the expression of Cx37 was 
demonstrated in osteoclasts, osteoblasts, and osteocytes [26,27], and its ubiquitous deletion 
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leads to decreased bone mass due to defective osteoclast differentiation, and altered bone 
matrix composition [27,28].
Less is known regarding the role of connexins in bone regeneration. A study investigated the 
consequences of Cx43 deletion from osteoblastic cells expressing the human osteocalcin 
promoter driving the Cre recombinase (OCN-Cre) in a model of closed femur fracture 
induced by 3-point bending [29]. Cx43 deficient mice exhibited reduced bone formation and 
resorption at the fracture site, lower mineralization, and abnormal biomechanical properties, 
indicating that Cx43 expression in osteoblastic cells is required for proper fracture healing. 
This phenotype contrasts with the one observed in long bones, in which both bone formation 
and resorption are increased in mice with deletion of Cx43 in OCN-expressing cells [20,21].
Recent studies describe the skeletal consequences of expression of a truncated Cx43 mutant 
lacking the carboxi-terminus domain Cx43ΔCT [30]. The first publication reported that 
female mice expressing one allele of the truncated Cx43 and one floxed Cx43 allele 
(Cx43ΔCT/fl mice) exhibit reduced cancellous bone mass due to defective bone formation, 
without any apparent cortical bone phenotype [31]. Furthermore, the Cx43ΔCT mutant 
reversed the cortical bone phenotype and the increased osteocyte apoptosis resulting from 
deletion of osteocytic Cx43. On the other hand, a study using male mice showed that 
cx43Δct/-mice expressing only the truncated Cx43 exhibit a phenotype similar to that of mice 
lacking Cx43 in osteoblasts and osteocytes, with increased periosteal diameter, marrow 
cavity area, and moment of inertia, and no change in cancellous bone volume/tissue volume 
[32]. These results indicate a sexually dimorphic role of Cx43 in bone. Whether these 
differences are due to the presence of different sex steroids in males versus females or to 
other factors remains to be determined.
The role of pannexins in bone has started to be uncovered in recent years [3]. All three 
members of this family, pannexin (Panx) 1, Panx2 and Panx3 are expressed in osteoblasts, 
osteocytes and osteoclasts [1]. Panx1 is the most widely distributed pannexin, found in 
osteoblastic cells among other cells and tissues. Panx3 exhibits a more restricted pattern of 
expression in the body, but it is also expressed in osteoblastic cells, and its expression 
increases as osteoblastic cells differentiate [33]. Panx2 was thought to be expressed only in 
the central nervous system, but was recently found also in osteoblastic cells and is present in 
extracellular vesicles released by mineralizing osteoblasts [34]. The role of pannexin 
channels in bone has not been investigated in great detail. Panx1 knockout mice showed no 
changes in diaphyseal structure when compared to wild type mice, but, unlike wild type 
mice, did not exhibit increased intracortical resorption when subjected to fatigue loading 
[35]. However, the bone mass or the cancellous bone architecture of these mice has not been 
reported. Panx3 knockout mice exhibit shorter long bones with a higher moment of inertia 
compared to wild type mice, without changes in bone mineral density [36]. Again, the 
phenotype of cancellous bone was not investigated in these mice.
Connexins and the aging skeleton
In addition to its role in bone development, reduced expression and function of Cx43 has 
been shown with aging. The increase in gap junction communication induced by parathyroid 
hormone is reduced in osteoblastic cells isolated from calvaria bones from old rats (12-, and 
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24–28-month-old) compared to young, 4-month-old animals [37]. This study did not find 
changes in Cx43 mRNA or protein in these osteoblastic cells or in basal gap junction 
communication, suggesting an intrinsic defect on the function of Cx43 gap junctions in 
response to parathyroid hormone. However, Cx43 expression in osteocyte-enriched whole 
bone measured by qPCR and by western blotting [38] and in osteocytes assessed by 
immunohistochemistry [39] is decreased in old mice. The discrepancy among these studies 
suggests that the reduction in Cx43 expression with aging likely occurs in osteocytes, and 
not in osteoblasts. Consistent with this notion, Cx43 deletion from osteocytes renders a 
phenotype that resembles that of old animals [40] with increased osteocyte apoptosis and 
enhanced endocortical resorption and periosteal apposition [19,21]. Furthermore, deletion of 
Cx43 from osteocytic MLO-Y4, but not from osteoblastic Ob-6, cells leads to spontaneous 
cell death in culture [38]. The later study showed that Cx43 restrains osteocyte death by 
maintaining the levels of the microRNA miR21, with the consequent reduction of the 
expression of the phosphatase and tensin homolog PTEN, resulting in the preservation of the 
Akt-survival pathway. Osteocyte apoptosis results in the release of pro-osteoclastogenic 
molecules RANKL and high mobility group box 1 (HMGB1), leading to increased 
osteoclastic bone resorption in the vicinity of apoptotic osteocytes. Future studies will 
determine whether by maintaining Cx43 levels high, some of the deleterious effects of aging 
on the skeleton can be avoided.
Connexin and pannexin gene mutations and bone disease
Mutations of the Cx43 gene (GJA1) were found in individuals with oculodentodigital 
dysplasia (ODDD), a condition associated with craniofacial and limb abnormalities [41]. 
These mutations do not have homogeneous consequences, and render proteins unable to 
form channels or with altered channel permeability. The original study described 17 
different mutations, and in the subsequent years at least 76 GJA1 mutations have been linked 
to ODDD [41–67]. In the early 2000s, a mouse model of ODDD expressing the mutant 
Cx43G60S allele was generated using N-ethyl-N-nitrosourea mutagenesis [68]. These mice 
exhibit craniofacial, limb, and dental abnormalities similar to those of humans with ODDD, 
including thin cortical bone, enlarged marrow cavity, and reduced bone mineral density, 
cancellous bone volume and mechanical strength. Another mouse model of ODDD was 
generated by expressing Cx43G138R in osteochondroprogenitors [17]. These mice exhibit 
smaller skulls, reduced bone mineral density and cortical thinning.
While all the patients with ODDD were found to exhibit mutations in the Cx43 gene, not all 
Cx43 mutations lead to ODDD. Thus, the Cx43R239Q mutant results in craniometaphyseal 
dysplasia [69], and Cx43E42K and Cx43S272P have been associated with sudden infant 
death [70]. In addition, patients homozygous for the recessive mutation Cx43R76H exhibit 
Hallermann-Streiff syndrome characterized by small stature, beaked nose, skeletal 
anomalies, and teeth defects, in addition to characteristics of ODDD [61].
More recently, the first patient with a mutation in the Panx1 gene was described [71]. A 
female expressing the Panx1R217H mutant exhibited kyphosis, among other abnormalities. 
In vitro studies showed that this mutated gene renders a protein with normal subcellular 
Plotkin et al. Page 4
Curr Osteoporos Rep. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
localization and glycosylation, but with defective channel permeability and reduced ability 
to release ATP.
In summary, both connexins and pannexins expressed in bone cells are essential for the 
development and adaptation of bone. Studies summarized elsewhere [72–75] demonstrated 
the role of Cx43 in the response to several bone-targeting stimuli and the intracellular 
signaling pathways mediated by Cx43 as part of intercellular gap junction channels, 
hemichannels, or channel-independent functions. Whether pannexins also can mediate the 
effect of stimuli that alter bone cell number or function remains to be determined.
CONNEXINS AND PANNEXINS IN SKELETAL MUSCLE
Gap junctions and hemichannels in normal skeletal muscles
Undifferentiated myoblasts express Cx43 and Cx45, proteins that form gap junction 
channels involved in coordinating the differentiation response induced by extracellular ATP 
[76]. During the late stage of differentiation myotubes transiently express Cx39 that appears 
to reduce the rate of differentiation [77], but its functional role remains largely unknown. 
Also, to the best of our knowledge, the possible role of connexin hemichannels in myoblast 
proliferation and/or differentiation has not been reported. Upon innervation the expression of 
the three connexins is down-regulated and are not expressed in differentiated myofibers. In 
adult muscles, satellite cells express Cx43 and Cx45 and upon muscle damage, satellite cells 
proliferate and form new myofibers in a connexin-dependent manner, as evidenced by the 
findings that in the absence of these proteins regeneration response is drastically reduced 
[78,79].
In undifferentiated myoblasts, Panx3 is required for cell proliferation and is down-regulated 
in differentiating myoblasts [80]. Moreover, undifferentiated myoblasts express a low 
amount of Panx1, which increases significantly during differentiation reaching maximal 
levels in fully differentiated cells [80]. Despite the low levels of Panx1 in undifferentiated 
myoblasts, the pannexin plays a critical role in acquisition of muscle cell commitment [81] 
and differentiation [80,81]. Further, electrical stimulation of myotubes promotes opening of 
Panx1 channels causing ATP release and affecting gene expression [82], suggesting that 
Panx1 might play a relevant role in muscle plasticity.
Fully differentiated myofibers express Panx1 that is localized in T-tubules and form channels 
through which ATP is released to the extracellular medium [83,84] where it activates P2 
receptors, inducing potentiation of the muscle contraction [83]. This response is not 
detectable in muscles from Panx1-/- mice and it is blocked by Panx1 channel inhibitors [83].
In resting muscles, Panx1 is phosphorylated and repetitive electrical stimulation of 
myofibers enhances the phosphorylation state of Panx1 in serine and threonine residues [83]. 
However, the protein kinase that mediates this effect has not yet been identified.
Connexin and pannexin1-based channels in diseases of skeletal muscles
Although the etiology of skeletal muscle diseases can vary significantly (e.g., denervation or 
mutations in proteins such as dystrophin or dysferlin) they share several features including 
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progressive muscular fatigue, muscle wasting, inflammation, atrophy and muscle 
dysfunction. With regard to the inflammatory response, recent studies have unveiled the 
presence of two processes: 1) infiltration of cells of the innate immune system and 2) 
activation of the inflammasome expressed by myofibers; however, the relative relevance of 
each process on muscle degeneration and tissue dysfunction has been poorly studied.
Notably, mutated dystrophin in Duchenne muscular dystrophy (DMD) and Becker muscular 
dystrophy (BMD) or mutated dsyferlin in limb-girdle muscular dystrophy (LGMD) type 2B 
are frequently absent or its amount is greatly reduced. The latter appears to be the 
consequence of protein degradation activated by the inflammatory response. For instance, 
treatments that reduce the progression of the inflammatory response induce reappearance of 
the mutated protein [85], suggesting that progression of the inflammatory response promotes 
degradation of the mutated proteins. A common intracellular signal known to activate 
protein degradation and inflammation is an elevated intracellular free Ca2+ concentration 
and for that reason in the following section of this review we focus in mechanisms that 
explain the rise in intracellular Ca2+ concentration.
Role of connexin de novo expression in muscle atrophy induced by denervation or 
glucocorticoids
It has been long known that denervated muscles undergo atrophy and this response was 
preceded by an increase in sarcolemma permeability. Recently, it was demonstrated that 
adult denervated muscles express de novo several poorly selective membrane channels, 
including connexin hemichannels, P2X7 receptors, and TRPV2 channels, and up-regulation 
of Panx1 channels [86]. Connexin hemichannels were shown to permeabilize the 
sarcolemma to small molecules including Evans blue [86]. In addition, all these newly 
expressed channels are permeable to Ca2+ as well as to monovalent ions and therefore can 
drastically affect the electrochemical gradient across the sarcolemma. Interestingly, the 
absence of just Cx43 and Cx45 expression was sufficient to avoid the ionic imbalance (e.g., 
increase in intracellular Ca2+ and Na+ signal) induced by denervation [87], suggesting that 
despite the persistent expression of Cx39, TRPV2 channels, P2X7 receptors, and Panx1 
channels, myofibers can handle the ionic imbalance caused by these channels and/or these 
channels are not fully functional. Furthermore, Cx39 hemichannels are not permeable to 
Ca2+ [88] and therefore they might be less toxic to denervated myofibers than Cx43 and 
Cx45 hemichannels.
The permeability of Cx43 and Cx45 hemichannels to Ca2+ [89,90] explains the activation of 
the inflammasome, protein degradation via ubiquitin proteasome pathway and atrophy of 
denervated fast myofibers [86,87]. The latter is strongly supported by the fact that 
denervated Cx43/Cx45 KO myofibers show a drastic reduction in protein degradation as 
well as in protein synthesis (reduced negative protein balance) and atrophy is strongly 
reduced (by ~75%). In contrast, Panx1 KO myofibers show similar atrophy to that of wild 
type myofibers upon denervation, indicating that upregulation of this channel does not play a 
critical role in the denervation-induced muscle degeneration.
An unexpected and recent finding was that de novo expression of connexin hemichannels 
explain the glucocorticoid-induced skeletal muscle atrophy [91], a condition frequently 
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observed in patients under chronic treatment with glucocorticoids due to inflammatory 
conditions. Myofibers deficient in Cx43 and Cx45 expression do not undergo atrophy after 
chronic treatment with dexamethasone, a synthetic glucocorticoid widely used in long term 
clinical treatments. Again, the de novo expression of connexin hemichannels promotes 
activation of the inflammasome in myofibers, indicating that glucocorticoids broadly known 
as anti-inflammatory agents, indeed act as anti-inflammatory compounds on the immune 
system but are inflammatory on skeletal muscles, which constitute approximately 50% of 
the body mass. Hence, inflamed muscles release pro-inflammatory cytokines that might 
affect other organs including bones.
Connexins in muscular dystrophies
Denervated skeletal muscles undergo a connexin-driven inflammation without the 
involvement of immune cells [86], but muscular dystrophies present both infiltration of 
immune system cells and activation of the myofibers inflammasome. For instance, mutations 
in dystrophin in DMD or BMD muscular dystrophy and mutations of dysfernil in LGMDs 
lead to severe and still incurable symptoms and lead to progressive myofiber apoptosis 
and/or necrosis ending in muscle dysfunction. All these diseases present inflammatory 
responses. In fact, the mdx mouse, model of DMD and BMD, shows ~30% of differential 
expression of genes related to inflammation [92,93], underlying the relevance of 
inflammation in these condition. In agreement with this statement, depletion or reduction of 
CD4+ or CD8+ T cells [94] or neutrophils [95] in mdx mice reduces the severity of the 
dystropathology. In addition, mdx myofibers were recently shown to express de novo three 
connexins (39, 43 and 45) [96]. Accordingly, myofibers of DMD or BMD patients were 
found to express connexins 45. 43 and 40.1 (ortholog of mouse Cx39) [85], suggesting that 
these proteins could play a relevant role in these pathological conditions. Interestingly, 
streptomycin has been found to reduce stretch-induced membrane permeability in mdx 
muscles [97] and is also known to block connexin hemichannels [98].
In vivo, the newly expressed Cx39, Cx43 and Cx45 in mdx myofibers form functional 
hemichannels in the sarcolemma [85]. Since all these membrane channels found in the 
sarcolemma are poorly selective, the electrochemical gradient is drastically reduced, which 
can explain the increase in cytoplasmic Ca2+ [99] and Na+ [100] concentrations. In addition, 
it is highly possible that the permeability to Ca2+ of the aforementioned channels induce 
Ca2+ overload in myofibers of mdx mice as well as DMD and BMD patients and promotes 
cell death. In agreement, mdx myofibers deficient in Cx43 and Cx45 do not exhibit high 
basal cytoplasmic Ca2+ signal or cell death by apoptosis and muscle dysfunction is greatly 
reduced [85].
Notably, the newly expressed poorly selective channels in mdx myofibers are accompanied 
by an increase in the levels of pro-inflammatory cytokines (e.g., IL-1β and TNF-α), 
inducible nitric oxide synthase (iNOS) and activated NFκB. All these responses are not 
detectable in myofibers of mdx mice deficient in Cx43/Cx45 expression [85], suggesting 
that early in the pathogenesis of DMD or BMD, the activation of inflammasome occurs and 
is induced by the action of functional connexin hemichannels.
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Mutations in dysferlin, a protein proposed to participate in membrane repair after damage 
[101], explain the LGMDs. In adult muscles, dysferlin is clearly expressed in myofibers and 
is mainly localized in the sarcolemma forming part of the transversal tubule membrane 
system [102]. With regard to inflammation, animal models show up-regulation of the 
inflammatory proteins Spp1 and S100a9 [103], suggesting that inflammation play a critical 
role in muscle degeneration. Also, the absence of dysferlin induced the activation of 
inflammasome in skeletal muscles [104]. In agreement with a local inflammatory response 
and the role of connexin hemichannels, it was recently demonstrated that connexin 
hemichannels also participate in LGMDs. In immortalized myotubes derived from patients 
harboring dysferlin mutations, it was found that connexin hemichannels are still expressed in 
mature myotubes and are responsible of an increase (~10%) of basal cytoplasmic Ca2+ 
levels, suggesting that these hemichannels could mediate the posterior muscle atrophy and 
adult myofibers death [96].
A final product of infiltrated inflammatory cells and activation of the inflammasome of 
myofibers is the generation and release of pro-inflammatory cytokines, which has been 
shown to promote the expression of connexin hemichannels in freshly isolated myofibers 
[105]. Therefore, the expression of connexins in normal differentiated muscles is repressed 
and several extracellular ligands can de-repress their expression. One of these mechanisms 
seems to be the lack of a neuron-derived factor in denervated myofibers [106]. A second 
mechanism could be the direct induction in connexin expression, as in the case of 
glucocorticoids known to induce the expression of Cx43 [91], and a third mechanism could 
involve the role of pro-inflammatory mediators, as described above. And of course, under 
certain conditions two or all three mechanisms could act in an orchestrated fashion with a 
more negative outcome for skeletal muscle functions.
In summary, the mechanism that induces the expression of connexin hemichannels in 
denervated muscle, under chronic treatment with glucocorticoids and in muscle dystrophies 
most likely differ. These three conditions share a common denominator, the expression of 
connexin hemichannels. Moreover, all of them present an increase in sarcolemma 
permeability to ions and small molecules leading to activation of the inflammasome. These 
findings also indicate that a great deal of the muscle dysfunction of all the above mentioned 
conditions is the result of inflammation rather than the cause of the disease. Therefore, 
connexin hemichannels could be regarded as new molecular targets to reduce the negative 
outcome of inflammation and might be beneficial to treat diverse muscle pathological 
conditions.
Conclusions
Studies of the last decade have revealed that connexins and pannexins are fundamental for 
the development, maintenance and regeneration of both bone and muscle. Moreover, these 
molecules, either as part of intercellular gap junction channels, as hemichannels or as 
channel independent signaling molecules, mediate the effect of stimuli that target the 
musculoskeletal system and are involved in the pathophysiological changes in both genetic 
and acquired diseases. The continuous advancements in this field will allow for the 
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development of new strategies that might target the musculoskeletal system to improve bone 
and skeletal muscle health.
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